摘要
肺纤维化起病隐匿,病因复杂,目前尚无特效药。现代研究表明肺纤维化的过程涉及多种细胞信号传导通路,如转化生长因子-β1 (TGF-β1)/Smad、丝裂原活化蛋白激酶(MAPK)、Wnt/β-连环蛋白(β-catenin)等,各种细胞因子在其中起着重要作用。通过查阅大量文献,发现肺纤维化的发生发展与基质金属蛋白酶类(MMPs)/基质金属蛋白酶抑制剂(TIMPs)、辅助性T细胞1 (Th1)/辅助性T细胞2 (Th2)、尿激酶型纤溶酶原激活物(uPA)/纤溶酶原激活物抑制剂-1 (PAI-1)这三类细胞因子密切相关,而单味中药成分能够通过调节这些细胞因子的平衡干预肺纤维化的进程,从而在一定程度上起到预防和治疗肺纤维化的作用。
The onset of pulmonary fibrosis is not clear,whose etiology is complex,and there is no specific drug for it at present. Modern studies have shown that the process of pulmonary fibrosis involves a variety of cell transduction signal pathways, such as transforming growth factor-β1(TGF-β1)/Smad, mitogen activated protein kinase(MAPK), Wnt/β-catenin,etc,and various cytokines play an important role in it. Through consulting a large number of literature,it is found that the occurrence and development of pulmonary fibrosis are closely related to three types of cytokines: matrix metall oproteinase(MMPs)/tissue inhibitor of metalloproteinase(TIMPs), T helper cell 1(Th1)/T helper cell 2(Th2), and urokinasetype plasminogen activator(uPA)/plasminogen activator inhibitor-1(PAI-1). What’s more, single Chinese medicine component can interfere with the process of pulmonary fibrosis by regulating the balance of these cytokines,thus playing a role in preventing and treating pulmonary fibrosis to a certain extent.
作者
潘照
包洁
PAN Zhao;BAO Jie
出处
《新中医》
CAS
2021年第19期24-27,共4页
New Chinese Medicine
基金
国家自然科学基金项目(81803980)。
关键词
肺纤维化
单味中药成分
细胞因子平衡
文献综述
Pulmonary fibrosis
Single Chinese medicine component
Cytokine balance
Literature review
